+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mycoplasma Testing - Global Strategic Business Report

  • PDF Icon

    Report

  • 158 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805303
The global market for Mycoplasma Testing was estimated at US$1.1 Billion in 2023 and is projected to reach US$1.9 Billion by 2030, growing at a CAGR of 8.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

What Is Mycoplasma Testing and Why Is It Essential in Biopharmaceuticals and Cell Cultures?

Mycoplasma testing refers to the detection of mycoplasma contamination in cell cultures, biopharmaceutical products, and vaccines. Mycoplasmas are a group of bacteria that lack a cell wall and can cause contamination in cell cultures used in biopharmaceutical production. Due to their small size and flexibility, they can pass through conventional filters and contaminate biotechnological processes without detection, compromising product safety and efficacy. Mycoplasma contamination can lead to alterations in cell physiology, inaccurate experimental results, and product recalls, making routine testing essential in laboratories, pharmaceutical companies, and biopharmaceutical production facilities. Testing for mycoplasma is critical for ensuring compliance with regulatory standards and maintaining the integrity of cell-based products used in medical treatments and research.

How Are Technological Advances Shaping Mycoplasma Testing Methods?

Technological innovations are significantly improving the accuracy, speed, and reliability of mycoplasma testing. Traditionally, mycoplasma detection was performed using culture-based methods, which are time-consuming and labor-intensive, taking weeks to yield results. However, advancements in molecular diagnostics, such as polymerase chain reaction (PCR) and real-time PCR (qPCR), have revolutionized mycoplasma testing by enabling faster, more sensitive, and specific detection of contamination. Additionally, nucleic acid amplification techniques (NAATs) and next-generation sequencing (NGS) technologies are further enhancing detection capabilities, allowing for the identification of a broader range of mycoplasma species. Automated testing platforms are also reducing the time and labor required for routine testing, making it easier for laboratories and production facilities to ensure contamination-free environments in real-time.

How Are Regulatory Requirements and Industry Standards Impacting the Demand for Mycoplasma Testing?

Stringent regulatory requirements in biopharmaceutical production and the increasing demand for safe and effective biotechnological products are driving the demand for mycoplasma testing. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate routine mycoplasma testing for cell-based products, biologics, and vaccines to ensure product safety and prevent contamination. Compliance with these regulations is critical for pharmaceutical companies to maintain product approval and avoid costly delays or recalls. The growing biopharmaceutical industry, along with the expansion of contract research organizations (CROs) and contract manufacturing organizations (CMOs), is also pushing the adoption of faster and more reliable mycoplasma testing methods. Moreover, with the rise in cell and gene therapies, where contamination risks can significantly affect product viability, the need for stringent testing protocols has become even more essential.

What Are the Key Growth Drivers in the Mycoplasma Testing Market?

The growth in the mycoplasma testing market is driven by several factors, including advancements in molecular diagnostics, increased regulatory scrutiny, and the expansion of biopharmaceutical production. The shift toward faster and more precise testing methods, such as PCR and NGS, is enhancing contamination detection, making these technologies increasingly popular in the industry. The rising prevalence of biologics, vaccines, and cell-based therapies is also contributing to the growing demand for reliable mycoplasma testing, as these products are particularly susceptible to contamination. Additionally, regulatory requirements mandating regular testing of biologics and cell cultures are further pushing the adoption of advanced mycoplasma detection solutions. The growing use of contract research and manufacturing services in the pharmaceutical industry is another driver, as these organizations require robust testing protocols to ensure compliance and product safety. Lastly, the increasing focus on quality control in biotechnological processes is promoting the continuous development of more efficient and automated testing platforms, further accelerating market growth.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Mycoplasma Testing Assays, Kits & Reagents segment, which is expected to reach US$940.8 Million by 2030 with a CAGR of a 9.4%. The Mycoplasma Testing Services segment is also set to grow at 8.1% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $274.3 Million in 2023, and China, forecasted to grow at an impressive 12.7% CAGR to reach $483.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Mycoplasma Testing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mycoplasma Testing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Mycoplasma Testing Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as American Type Culture Collection (ATCC), Biological Industries Israel Beit Haemek Ltd., Biounique Testing Laboratories Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 11 Featured):

  • American Type Culture Collection (ATCC)
  • Biological Industries Israel Beit Haemek Ltd.
  • Biounique Testing Laboratories Inc.
  • Charles River Laboratories International, Inc.
  • Invivogen
  • Lonza Group AG
  • Merck KgaA
  • Norgen Biotek Corporation
  • Promocell GmbH
  • Roche Diagnostics (Schweiz) AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • Wuxi Apptec Co., Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Mycoplasma Testing - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Adoption of Biopharmaceuticals Spurs Demand for Mycoplasma Testing in Manufacturing
  • Increasing Regulatory Scrutiny Expands Addressable Market for Mycoplasma Testing in Drug Development
  • Technological Advancements in PCR-Based Testing Strengthen Business Case for Rapid Mycoplasma Detection
  • Growth in Cell Culture-Based Research Drives Adoption of Routine Mycoplasma Testing in Laboratories
  • Increasing Use of Mycoplasma Testing in Gene and Cell Therapies Expands Market for Advanced Testing Solutions
  • Rising Focus on Contamination Control in Biomanufacturing Propels Growth in Mycoplasma Testing Services
  • Expansion of Contract Research Organizations (CROs) Fuels Demand for Outsourced Mycoplasma Testing
  • Increasing Investment in Vaccine Development Strengthens Market for Mycoplasma Testing in Biopharma R&D
  • Expansion of Stem Cell Research and Regenerative Medicine Spurs Demand for Mycoplasma Testing in Cell Cultures
  • Technological Innovations in Digital PCR Propel Growth in Sensitivity and Speed of Mycoplasma Detection
  • Rising Demand for Mycoplasma-Free Biological Products Drives Adoption of Testing Protocols in Drug Development
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Mycoplasma Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Mycoplasma Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Mycoplasma Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Mycoplasma Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Assays, Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Assays, Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Assays, Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Staining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Staining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Staining by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Cell Line Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Cell Line Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Cell Line Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for End-of-Production Cell Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for End-of-Production Cell Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for End-of-Production Cell Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 33: World Historic Review for Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: World 16-Year Perspective for Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Mycoplasma Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • American Type Culture Collection (ATCC)
  • Biological Industries Israel Beit Haemek Ltd.
  • Biounique Testing Laboratories Inc.
  • Charles River Laboratories International, Inc.
  • Invivogen
  • Lonza Group AG
  • Merck KgaA
  • Norgen Biotek Corporation
  • Promocell GmbH
  • Roche Diagnostics (Schweiz) AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • Wuxi Apptec Co., Ltd.

Table Information